Page 6,538«..1020..6,5376,5386,5396,540..6,5506,560..»

Drugs police arrest four in York raids

Posted: Published on September 6th, 2012

Drugs police arrest four in raids on Bramham Grove, in Chapelfields, York 12:00pm Thursday 6th September 2012 in News Exclusive By Jennifer Bell, Crime reporter Two men are arrested after police raid homes in Bramham Grove, Chapelfields, York FOUR people were arrested and a haul of cannabis plants seized when police raided three houses in the same street in York. Police officers and PCSOs swooped on Bramham Grove, in Chapelfields, shortly after 8am yesterday to execute the warrants. On bursting into one house, officers found 20 cannabis plants growing in a loft, as well as a haul of drug paraphernalia. A 29-year-old man and a 47-year-old woman were later led from the property after being arrested on suspicion of cultivation of cannabis. They were taken into police custody. Officers who stormed two other properties on the terraced street brought out another two suspects. In one property, police arrested a 34-year-old man on suspicion of cultivation of cannabis after cannabis plants and drug paraphernalia were discovered in an outbuilding. Following a search of the second house a 33-year-old was arrested on suspicion of being concerned in the supply of a Class B drug after evidence of former cannabis growth was discovered. … Continue reading →

Posted in Drugs | Comments Off on Drugs police arrest four in York raids

VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund

Posted: Published on September 6th, 2012

SOURCE: VistaGen Therapeutics, Inc. SOUTH SAN FRANCISCO, CA--(Marketwire - Sep 6, 2012) - VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism screening, today announced that Platinum Long Term Growth VII, LLC (Platinum) purchased a $750,000 secured convertible promissory note from the Company, supplementing its purchase in July 2012 of a similar note in the principal amount of $500,000.VistaGen currently anticipates that all amounts due under the two notes will be rolled into a proposed financing by Platinum expected to result in gross proceeds to VistaGen of at least $3.25 million, including $1.25 million from the two outstanding notes. In addition, VistaGen announced the strategic restructuring of approximately $2.38 million of long-term indebtedness to Morrison & Foerster LLP (M&F), its intellectual property counsel. The restructuring is expected to result in VistaGen's issuance of restricted common stock to M&F, at a price of $1.00 per share, as payment for approximately $1.38 million of the principal amount of such long-term indebtedness. "We are very pleased with these recent endorsements from our largest institutional investor and our highly-regarded, long-time intellectual property counsel," … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund

StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease …

Posted: Published on September 6th, 2012

NEWARK, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that the California Institute for Regenerative Medicine (CIRM) has approved an award to the Company for up to $20 million under CIRM's Disease Team Therapy Development Award program (RFA 10-05). The award is to fund preclinical development of StemCells' proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in Alzheimer's disease over a maximum four-year period, with the goal of filing an investigational new drug (IND) application for a clinical trial in that time. In July, CIRM approved a separate award to the Company under RFA 10-05 for up to $20 million to fund preclinical development of HuCNS-SC cells in cervical spinal cord injury. "With the recent spate of late-stage clinical failures in Alzheimer's disease, it is clear that the field could benefit from alternative approaches to lessen the huge burden on families, caregivers and our healthcare system," commented Martin McGlynn, President and CEO of StemCells, Inc. "Our recently reported preclinical data, which showed that our neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease, shows our approach has promise. We greatly appreciate the support from CIRM, which should … Continue reading →

Posted in Stem Cell Human Trials | Comments Off on StemCells, Inc. Awarded $20 Million From the California Institute for Regenerative Medicine for Alzheimer's Disease …

Cyberonics To Participate In Upcoming September Investor Conferences

Posted: Published on September 6th, 2012

HOUSTON, Sept.6, 2012 /PRNewswire/ --Cyberonics, Inc. (CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced it will participate in the following conferences in September. Greg Browne, Cyberonics' Chief Financial Officer, will present at the UBS Global Life Sciences Conference on Wednesday, September 19, 2012 at 3:00 PM Eastern Time. A live audio webcast of the presentation can be accessed by clicking on the Investor Relations link on the Cyberonics home page at http://www.cyberonics.com on September 19, 2012. Mr. Browne will also present at the Credit Suisse 3rd Annual Small and Mid-Cap Conference on Thursday, September 20, 2012 at 4:30 PM Eastern Time.The conference sessions will not be webcasted and no slides will be presented at the conference. About Cyberonics, Inc. and the VNS Therapy System Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve.Cyberonics markets the VNS Therapy System in selected markets worldwide. Additional information on Cyberonics and the VNS Therapy System is … Continue reading →

Comments Off on Cyberonics To Participate In Upcoming September Investor Conferences

BU Establishes New Autism Research Center

Posted: Published on September 6th, 2012

$10 million National Institutes of Health grant will allow researchers to understand why some people with autism never develop spoken language skills Newswise (Boston) Boston University College of Arts & Sciences (CAS) Professor of Psychology Helen Tager-Flusberg has been named the director of a new Autism Center of Excellence (ACE), to be located at BU. The ACE will be funded by a five-year, $10 million grant from the National Institutes of Health. The center will support a set of research projects designed to address the question of why an estimated 25-30% of the autism population never acquires spoken language skills, even after years of conventional therapies. Little is known about this group of children and adults, as they have rarely been included in studies on autism. The BU ACE is the first center to be established to address the critical needs of this neglected end of the autism spectrum. The research will focus on: the development of novel methods for assessing this population using innovative technologies; brain and behavioral studies that will identify the reasons why these individuals fail to acquire spoken language; and evaluation of an innovative behavioral intervention called Auditory Motor Mapping Training, or AMMT, that has shown … Continue reading →

Comments Off on BU Establishes New Autism Research Center

Can videogaming benefit young people with autism spectrum disorder?

Posted: Published on September 6th, 2012

ScienceDaily (Sep. 5, 2012) According to the Centers for Disease Control and Prevention (CDC), 1 in 88 children in the U.S. has autism spectrum disorder (ASD), a broad group of neurodevelopmental disorders. Children and adolescents with ASD are typically fascinated by screen-based technology such as video games, and these can be used for educational and treatment purposes, as described in an insightful Roundtable Discussion published in Games for Health Journal: Research Development, and Clinical Applications, a peer-reviewed publication from Mary Ann Liebert, Inc. Individuals with ASD have difficulty with communication and social interaction, but they often have particularly good visual perceptual skills and respond well to visual stimuli. Videogames offer opportunities for successful learning, motivation to improve skills such as planning, organization, and self-monitoring, and reinforcement of desired behaviors without the need for direct human-to-human interaction. Autism is a growing area of interest for the gamification community, and Games for Health Journal continues to explore various aspects of how videogame technology can be beneficial in treating this complex spectrum of disorders. In a previous issue of the Journal, the article "Comparing Energy Expenditure in Adolescents with and without Autism while Playing Nintendo Wii Games" (http://online.liebertpub.com/doi/full/10.1089/g4h.2011.0019) described how gaming might help … Continue reading →

Comments Off on Can videogaming benefit young people with autism spectrum disorder?

Robotic exoskeletal device: Preliminary research findings for Ekso in spinal cord injury

Posted: Published on September 6th, 2012

ScienceDaily (Sep. 5, 2012) Preliminary research findings have been released from a clinical study of the wearable robotic exoskeletal device, Ekso (Ekso Bionics). Initial results are promising for the potential application of Ekso-assisted walking in rehabilitation, in exercise/wellness programs, in the community and for home use. Kessler Foundation has released preliminary research findings from its clinical study of the wearable robotic exoskeletal device, Ekso (Ekso Bionics). Gail Forrest, PhD, assistant director of Human Performance and Engineering Research, presented the Ekso research data on September 3, at the meeting of the Academy of Spinal Cord Injury Professionals at the Rio Suites in Las Vegas. Dr. Forrest directs mobility research at the Foundation, including activity-based locomotor therapy, functional electrical stimulation, and treadmill training with the LokomatPro v6, as well as Ekso. Her research focuses on new ways to improve function and restore mobility for people with disabilities and reduce their long-term risks for complications. Ekso, has been undergoing clinical investigation in patients with spinal cord injury at Kessler since October 2011, when the research team received the second commercial unit distributed by Ekso Bionics. "Our initial research results are promising for the potential application of Ekso-assisted walking in rehabilitation, in exercise/wellness programs, … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Robotic exoskeletal device: Preliminary research findings for Ekso in spinal cord injury

InVivo to Present at 14th Annual Rodman and Renshaw Annual Healthcare Conference

Posted: Published on September 6th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for thetreatment of spinal cord injuries(SCI) and neurotrauma conditions, today announced that CEO Frank Reynolds is scheduled to present to investors at the 2012 14th Annual Rodman and Renshaw Healthcare Conference to be held September 9-11, 2012 at the Waldorf Astoria in New York City. InVivos presentation will be on Tuesday, September 11th at 10:00 a.m. EDT in the Starlight Center room. A live webcast will be available at http://www.wsw.com/webcast/rrshq22/nviv. Additional information about the 2012 14th Annual Rodman and Renshaw Healthcare Conference can be found at: http://www.rodm.com/conferences. About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on InVivo to Present at 14th Annual Rodman and Renshaw Annual Healthcare Conference

PropThink: Data from Acadia by the End of 2013 but a Capital Raise Likely as Well

Posted: Published on September 6th, 2012

After announcing Wednesday morning that it has completed enrollment of its latest Phase 3 Pimavanserin trial, dubbed the -020 study, Acadia Pharmaceuticals (NASDAQ:ACAD - News) gained 4% for the day, and is up 3% in early trading Thursday. Pimavanserin is an oral treatment for Parkinson's Disease Psychosis, for which there is no FDA approved treatment available in the U.S. Psychosis is often triggered by Parkinson's treatments themselves, which elevate dopamine levels in the brain to improve motor control but create detrimental neurological side effects like hallucinations and delirium. Pimavanserin has the opportunity to fill a large unmet medical need in the growing field of Parkinson's treatment, over half a million people domestically and if approved for other pursued indications, as many as 5 million people according to Acadia. But the product has faced setbacks in development, as detailed in a March 2012reportfrom Zack's. The drug failed an earlier Phase 3 study (-012) after a high placebo response rate did not show proof of efficacy for Pimavanserin. The company discontinued another Phase 3 trial (-014) and adjusted protocol, trial sites, and dosage before initiating trial -020 which the company believes will more accurately reflect Pimavanserin's effectiveness. Top-line data from the -020 … Continue reading →

Posted in Parkinson's Treatment | Comments Off on PropThink: Data from Acadia by the End of 2013 but a Capital Raise Likely as Well

Life after Parkinson’s

Posted: Published on September 6th, 2012

Sept. 6, 2012, 10:06 a.m. Despite the restrictions that Parkinsons Disease brings, John Coppens has adapted so that he can still do the things he enjoys. Coppens was diagnosed with Parkinsons 12 years ago at the age of 46 while working as a fitter at the steelworks. The first indication of the disease was a sore shoulder, followed by dyskinesia - involuntary movements. Its a hideous disease, Coppens says, sitting in his Corrimal lounge room with wife Anna. He relies on a walker to get around and carries a pump and tube that works all day to deliver Duodopa intestinal gel which controls the severe involuntary movements of advanced Parkinsons. Luckily, the Duodopa is being provided as part of a medical trial otherwise, Coppens says, it would cost about $76,000 a year to stay on the medication. Because the effectiveness of medication used to treat the disease wears off over time, Coppens has been through a myriad of treatments, including Apomorphine which requires 12 injections each day. Even now, with the intestinal gel, once Coppens turns off the pump at 10pm he can only sleep for about two hours before the movements increase and wake him up. And the medication … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Life after Parkinson’s

Page 6,538«..1020..6,5376,5386,5396,540..6,5506,560..»